Clinical Impact of New Rheumatoid Arthritis Findings From ACR/ARP 2020*

November 5-9, 2020; Virtual Meeting
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR/ARP 2020.

Highlights

Capsule Summary Slidesets

Preliminary results of this nonrandomized study suggest that 2 doses of the HZ/su vaccine produce satisfactory antibody responses and acceptable tolerability in a majority of patients with RA receiving JAK inhibitors.

Released: November 9, 2020

In a cohort of US patients with RA, neither an increased incidence of cardiac events nor increased mortality was observed with use of HCQ.

Released: November 11, 2020

In early RA, pharmacogenomics biomarkers may be useful in guiding effective RA treatment choices and need for treatment escalation.

Released: November 11, 2020

Flares more frequent with tapered vs continued TNF inhibitor during first 12 months (63% vs 5%, respectively).

Released: November 13, 2020

Pooled analysis of 5 phase III trials in RA suggests that history of VTE and higher BMI were risk factors for VTE in those receiving upadacitinib.

Released: November 9, 2020

In cross-trial post hoc analysis with mixed-effect model repeated measure adjustment, no evident differences in Week 24 endpoints (CDAI, DAS28-CRP, CRP, hemoglobin, pain VAS, FACIT-Fatigue) between patients receiving sarilumab with vs without MTX.

Released: November 10, 2020

Pooled analysis of 7 phase II/III trials suggests that the investigational JAK inhibitor is associated with low rates of VTE and MACE, with no major safety signals among those with cardiovascular risk factors.

Released: November 13, 2020

After first year of follow-up, no progression to inflammatory arthritis observed for 44% to 68% of ACPA-positive individuals, 66% to 89% of ACPA-negative individuals across cohorts.

Released: November 10, 2020

Pooled analysis of 2 North American cohorts finds high agreement between physicians and patients in distinguishing between active vs controlled RA.

Released: November 9, 2020

At Week 48, SDAI remission maintained in 49.5% of patients receiving etanercept monotherapy vs 28.7% of patients receiving methotrexate monotherapy.

Released: November 12, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue